Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $565,000.

  • Lineage Cell Therapeutics' Capital Expenditures fell 89.29% to $12,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $488,000, marking a year-over-year increase of 67.70%. This contributed to the annual value of $565,000 for FY2024, which is 16.17% down from last year.
  • Lineage Cell Therapeutics' Capital Expenditures amounted to $565,000 in FY2024, which was down 16.17% from $674,000 recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Capital Expenditures peaked at $674,000 during FY2023, and registered a low of $64,000 during FY2020.
  • In the last 3 years, Lineage Cell Therapeutics' Capital Expenditures had a median value of $565,000 in 2024 and averaged $550,667.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Capital Expenditures slumped by 85.45% in 2020, and later spiked by 431.25% in 2021.
  • Lineage Cell Therapeutics' Capital Expenditures (Yearly) stood at $64,000 in 2020, then surged by 431.25% to $340,000 in 2021, then increased by 21.47% to $413,000 in 2022, then skyrocketed by 63.20% to $674,000 in 2023, then dropped by 16.17% to $565,000 in 2024.